Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2012-09-30
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Interventional Pulmonology, Microbiota and Immune Response in the Patient With Lung Cancer
NCT05164445
Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator
NCT04352335
Immunological Markers Predictive of Response and Toxicity to Checkpoint Inhibitors in Non-small Cell Lung Cancer
NCT04918836
irAE Prediction of Anti-PD-1/L1 in Lung Cancer
NCT05288569
Correlation of Metabolic Imaging With Immune Markers in NSCLC Candidate to Immunotherapy.
NCT03563482
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lung cancer
Newly diagnosed and untreated non small cell lung cancer patients who underwent surgical resection for NSCLC (pathological stage I-III)
No interventions assigned to this group
Control
Subjects who will have surgery due to recurrent spontaneous pneumothorax Patients without lung cancer or other malignancies
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with histologically documented non-small cell lung cancer
* Control group - patients without non-small cell lung cancer
* Written (signed) Informed Consent to participate in the study
Exclusion Criteria
* Any unstable systemic disease (including active infections, significant cardiovascular disease)
* Prior chemotherapy or radiotherapy
* Autoimmune disease
* Nursing or pregnant women
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lithuanian University of Health Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marius Zemaitis
Assoc. Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marius Zemaitis, Assoc.Prof.
Role: PRINCIPAL_INVESTIGATOR
Lithuanian University of Health Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lithuanian University of Health Sciences
Kaunas, , Lithuania
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jackute J, Zemaitis M, Pranys D, Sitkauskiene B, Miliauskas S, Vaitkiene S, Sakalauskas R. Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunol. 2018 Jan 24;19(1):3. doi: 10.1186/s12865-018-0241-4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRLC-1109
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.